MD MBA - PYC Therapeutics Chief Operations

All Insiders . Australia . 
Stock . PYC Therapeutics . Stakeholders . Insider . MD MBA
PYC Stock   1.40  0.05  3.45%   

Executive

MD MBA is Chief Operations of PYC Therapeutics
Age 56
Address Harry Perkins Inst. of Medical Research, Nedlands, WA, Australia, 6009
Phone61 8 6151 0992
Webhttps://pyctx.com

PYC Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.3783) % which means that it has lost $0.3783 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6961) %, meaning that it generated substantial loss on money invested by shareholders. PYC Therapeutics' management efficiency ratios could be used to measure how well PYC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Total Current Liabilities is likely to gain to about 9.6 M in 2024. Liabilities And Stockholders Equity is likely to gain to about 95.8 M in 2024
PYC Therapeutics has accumulated 1.11 M in total debt. Debt can assist PYC Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, PYC Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PYC Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PYC to invest in growth at high rates of return. When we think about PYC Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Kul SinghRea Group
N/A
Corrie HassanFSA Group
N/A
Vanja KalabicLight Wonder
41
Owen JenningsBlock Inc
N/A
AMCT BAMacquarie Group
59
Andrew CassidyMacquarie Group
N/A
Angad SoinXero
N/A
Alexander SchirmeisterXero
N/A
Jennifer HorneryCochlear
N/A
Mike BrockBlock Inc
N/A
Steven StamstadLight Wonder
N/A
Anthony WaldronRea Group
N/A
Brian GrassadoniaBlock Inc
41
K WaldronTamawood
N/A
Ashley GrechXero
N/A
Nikhil DixitBlock Inc
N/A
Nick ZangariLight Wonder
N/A
Kate McLaughlinXero
N/A
Alice BennettRea Group
N/A
Mark ReesXero
N/A
Kirsty GodfreyBillyXero
N/A
PYC Therapeutics (PYC) is traded on Australian Securities Exchange in Australia and employs 5 people. PYC Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Return On Equity-0.7
Return On Asset-0.38

PYC Therapeutics Leadership Team

Elected by the shareholders, the PYC Therapeutics' board of directors comprises two types of representatives: PYC Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PYC. The board's role is to monitor PYC Therapeutics' management team and ensure that shareholders' interests are well served. PYC Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PYC Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
MD MBA, Chief Operations
Glenn Noronha, Chief Officer
BComm BCom, Company Secretary
Pr Fletcher, Chief Officer
GDLP JD, CEO Director

PYC Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PYC Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.7
Return On Asset-0.38
Profit Margin(1.71) %
Operating Margin(1.78) %
Current Valuation587.49 M
Shares Outstanding466.61 M
Shares Owned By Insiders59.23 %
Shares Owned By Institutions0.57 %
Price To Book8.12 X
Price To Sales29.61 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for PYC Stock Analysis

When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY